These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32685590)

  • 1. Healthcare Utilization, Costs of Care, and Mortality Among Psatients With Spinal Muscular Atrophy.
    Tan H; Gu T; Chen E; Punekar R; Shieh PB
    J Health Econ Outcomes Res; 2019; 6(3):185-195. PubMed ID: 32685590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare Utilization, Costs of Care, and Mortality Among Patients With Spinal Muscular Atrophy.
    Tan H; Gu T; Chen E; Punekar R; Shieh PB
    J Health Econ Outcomes Res; 2019; 6(3):185-195. PubMed ID: 37362080
    [No Abstract]   [Full Text] [Related]  

  • 3. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
    Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
    Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada.
    Chen G; Sharif B; Gerber B; Farris MS; Cowling T; Cabalteja C; Wu JW; Maturi B; Klein-Panneton K; Jean K Mah
    J Med Econ; 2021 Nov; 24(sup1):51-59. PubMed ID: 34906030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

  • 6. Economic burden of spinal muscular atrophy: an analysis of claims data.
    Belter L; Cruz R; Kulas S; McGinnis E; Dabbous O; Jarecki J
    J Mark Access Health Policy; 2020 Nov; 8(1):1843277. PubMed ID: 33224449
    [No Abstract]   [Full Text] [Related]  

  • 7. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
    Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
    Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management.
    Paracha N; Hudson P; Mitchell S; Sutherland CS
    Pharmacoeconomics; 2022 Apr; 40(Suppl 1):11-38. PubMed ID: 34761360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economic burden of spinal muscular atrophy.
    Armstrong EP; Malone DC; Yeh WS; Dahl GJ; Lee RL; Sicignano N
    J Med Econ; 2016 Aug; 19(8):822-6. PubMed ID: 27264163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant healthcare burden and life cost of spinal muscular atrophy: real-world data.
    Chan SHS; Wong CKH; Wu T; Wong W; Yu MKL; Au ICH; Chan GCF
    Eur J Health Econ; 2023 Nov; 24(8):1373-1382. PubMed ID: 36403177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare resource utilisation and direct medical cost for individuals with 5q spinal muscular atrophy in Sweden.
    Sejersen T; Graham S; Ekström AB; Kroksmark AK; Kwiatkowska M; Ganz ML; Justo N; Gertow K; Simpson A
    Eur J Health Econ; 2024 Apr; ():. PubMed ID: 38642267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spinal muscular atrophy: an update for managed care pharmacists.
    Pannier AD
    Am J Manag Care; 2021 Feb; 27(1 Suppl):S13-S18. PubMed ID: 33534992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Family, healthcare professional, and societal preferences for the treatment of infantile spinal muscular atrophy: A discrete choice experiment.
    Carey KA; Farrar MA; Kasparian NA; Street DJ; De Abreu Lourenco R
    Dev Med Child Neurol; 2022 Jun; 64(6):753-761. PubMed ID: 34962299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
    Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
    Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct Medical Costs of Spinal Muscular Atrophy in the Catalonia Region: A Population-Based Analysis.
    Darbà J
    Clin Drug Investig; 2020 Apr; 40(4):335-341. PubMed ID: 32144652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
    J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative All-Cause Mortality Among a Large Population of Patients with Spinal Muscular Atrophy Versus Matched Controls.
    Viscidi E; Juneja M; Wang J; Wang N; Li L; Farwell W; Bhan I; Makepeace C; Laird K; Kupelian V; Eaton S; Dilley A; Hall S
    Neurol Ther; 2022 Mar; 11(1):449-457. PubMed ID: 34936050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spinal muscular atrophy: epidemiology and health burden in children - a Polish national healthcare database perspective before introduction of SMA-specific treatment.
    Kostera-Pruszczyk A; Napiórkowski Ł; Szymańska K; Jędrzejczak J; Roszkowski M; Słowiński J; Frączek A; Ryglewicz D; Więckowska B
    Neurol Neurochir Pol; 2021; 55(5):479-484. PubMed ID: 34664710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.
    Darras BT; Farrar MA; Mercuri E; Finkel RS; Foster R; Hughes SG; Bhan I; Farwell W; Gheuens S
    CNS Drugs; 2019 Sep; 33(9):919-932. PubMed ID: 31420846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy.
    Lusakowska A; Jedrzejowska M; Kaminska A; Janiszewska K; Grochowski P; Zimowski J; Sierdzinski J; Kostera-Pruszczyk A
    Orphanet J Rare Dis; 2021 Mar; 16(1):150. PubMed ID: 33761963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.